Inhibiting ß-Catenin by ß-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.

Qin, Jiang-Jiang; Wang, Wei; Li, Xin; Deokar, Hemantkumar; Buolamwini, John K; Zhang, Ruiwen

Qin, Jiang-Jiang; Wang, Wei; Li, Xin; Deokar, Hemantkumar; Buolamwini, John K; Zhang, Ruiwen.

Afiliação

Qin JJ; Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.
Wang W; Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.
Li X; Center for Drug Discovery, University of Houston, Houston, TX, United States.
Deokar H; Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, United States.
Buolamwini JK; Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States.
Zhang R; Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States.

Front Pharmacol ; 9: 5, 2018.

Article em En | MEDLINE | ID: mdl-29387014

Palavras-chave

MDM2; p53; pancreatic cancer; protein degradation; ß-carboline; ß-catenin

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos